Nasus Pharma Ltd. (NSRX) Stock
Nasus Pharma stock price chart
NSRX stock quote & key statistics
Nasus Pharma annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0 | -$5.9M | -$0.23 |
| FY2024 | $0 | -$1.5M | -$0.09 |
| FY2023 | $0 | -$1.1M | — |
| FY2022 | $0 | -$1.7M | — |
Fiscal year ending December 31. Source: company filings via EODHD.
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Nasus Pharma stock FAQ
What is the Nasus Pharma stock ticker symbol?
Nasus Pharma Ltd. trades on the NYSE American under the ticker symbol NSRX.
What sector and industry is Nasus Pharma in?
Nasus Pharma Ltd. is classified in the Healthcare sector, Drug Manufacturers - General industry.
How many employees does Nasus Pharma have?
Nasus Pharma Ltd. has about 7 full-time employees.
What were Nasus Pharma's revenue and earnings last fiscal year?
Nasus Pharma reported revenue of $0 and net income of -$5.9M in fiscal 2025, with earnings per share of -$0.23.
When did Nasus Pharma go public?
Nasus Pharma stock began trading on August 13, 2025.